Fig. 2

The tumor targeting and PTT ability of HNP@RBCM-cRGD in vitro and in vivo. A Inverted representative optical microscope images of Hepa 1–6, CT26, and PANC-2 treated with HNP@RBCM-cRGD. Cell nuclei and membranes were labeled with DAPI and DiI, respectively (scale bar = 50 μm). B In vitro viability of Hepa 1–6 cells treated with PBS, RBCM-cRGD, HNP, and HNP@RBCM-cRGD at the concentration of 50 μg/mL with and without laser after 24 h. The illustration of the whole procedure was demonstrated in C. The temperature growing curve (D) and infrared thermal images of tumor-bearing mice intravenously injected with PBS, RBCM-cRGD, HNP, and HNP@RBCM-cRGD (same concentration: 1.5 mg/mL, 200 μL), followed by 808 nm laser irradiation (1.0 W/cm²) 24 h post-injection for 0 min, 2.5 min, 5 min, 7.5 min and 10 min E. Images of resected tumors were collected on day 10 from 32 mice in different groups (n = 4 in each group) (F) and relative tumor volumes were measured (G). The tumor weights (H) and body weights (I) of the mice after different treatments (error bars represent the mean ± s.d., one-way ANOVA was used for multiple comparisons; n = 4, ns P > 0.05, ***P < 0.001)